T. DEMİRER Et Al. , "Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels," Bone Marrow Transplantation , vol.17, no.4, pp.491-495, 1996
DEMİRER, T. Et Al. 1996. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplantation , vol.17, no.4 , 491-495.
DEMİRER, T., Buckner, C., Appelbaum, F., Bensinger, W., Sanders, J., Lambert, K., ... Clift, R.(1996). Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplantation , vol.17, no.4, 491-495.
DEMİRER, TANER Et Al. "Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels," Bone Marrow Transplantation , vol.17, no.4, 491-495, 1996
DEMİRER, TANER Et Al. "Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels." Bone Marrow Transplantation , vol.17, no.4, pp.491-495, 1996
DEMİRER, T. Et Al. (1996) . "Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels." Bone Marrow Transplantation , vol.17, no.4, pp.491-495.
@article{article, author={TANER DEMİRER Et Al. }, title={Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels}, journal={Bone Marrow Transplantation}, year=1996, pages={491-495} }